4DMedical Ltd (ASX: 4DX) shares took a breather during Friday’s session, edging 1% higher to $4.10.

The healthcare technology company has pulled back around 12% over the past six months and now trades roughly 46% below the record high it reached in April.

However, the longer-term picture looks very different. This ASX healthcare share is still up an astonishing 1,636% over the past 12 months. Yes, that’s more than sixteen-fold in just one year.

So, after such an extraordinary run, could 4DMedical shares eventually reclaim their all-time high?

Why investors have become so bullish

The biggest catalyst behind the remarkable rise of 4DMedical shares has been growing confidence in its commercial prospects.

The company has developed proprietary respiratory imaging technology that produces four-dimensional lung scans, giving doctors significantly more information than traditional imaging methods. The technology has applications across chronic respiratory diseases, lung cancer, and surgical planning.

Importantly, management has shifted its focus from proving the technology to commercialising it.

US growth and AI investments

Over the past year, 4DMedical has secured several significant contracts and partnerships across the US. Recently, the business signed a major agreement with SimonMed, helping expand its CT:VQ lung imaging technology across the US.

Management believes the deal could lift its addressable market to around US$3 billion with major healthcare providers and government agencies. These agreements have strengthened investor confidence that revenue growth can accelerate as adoption increases.

The company has also continued investing in artificial intelligence capabilities to expand the usefulness of its imaging platform and create additional opportunities within respiratory care.

The path back to record highs

For 4DMedical shares to revisit their April peak, investors will likely need further evidence that commercial momentum is translating into sustainable financial results.

Like many emerging healthcare technology companies, 4DMedical remains focused on scaling its business rather than generating large profits today. That means investors are placing significant value on its future growth potential.

Continued contract wins, increasing scan volumes, expanding recurring revenue, and progress in the US healthcare market could all help support a higher valuation over time.

Heavy investments in research

Despite its enormous gains, 4DMedical remains a higher-risk investment.

Commercialising new medical technology can take longer than expected. Particularly, when healthcare providers require clinical validation and budget approvals before adopting new products.

The company also faces competition from established medical imaging businesses and must continue investing heavily in research, product development, and sales to maintain its competitive advantage.

As a high-growth healthcare stock, 4DMedical shares are also likely to remain volatile. Even positive companies can experience large share price swings as investor sentiment shifts.

The post Up 1,636%, but can 4DMedical shares reclaim their record high? appeared first on The Motley Fool Australia.

More reading

• Which ASX 200 sectors paid the highest dividend yields in FY26?
• This red-hot ASX healthcare share hit a speed bump. What next?
• 13 ASX 200 shares that doubled in value in FY26
• 2 ASX 200 healthcare shares to buy after sector rebounds 23% in a month
• These are the 10 most shorted ASX shares

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Minerals 260 Ltd (ASX: MI6) this week released the results of a prefeasibility study into its Bullabulling gold project in Western Australia, and it’s fair to say the market was underwhelmed.

While the stock is up more than 440% over the past 12 months, the shares dipped slightly on the publication of the PFS and are now trading at 62 cents.

The analysts at Morgans believe this is cheap and have a bullish share price target on the gold company’s shares, which we’ll get to later.

First, let’s look at what they announced.

Major, long-life gold project in development

The company said in a statement to the ASX that Bullabulling would generate average annual free cash flow of $330 million and would operate for 19 years.

The company would spend $180 million from existing cash reserves to get to a final investment decision, while the mine would cost $560 million to build, plus another $115 million for pre-production operations.

A definitive feasibility study was expected to be completed in the first quarter of calendar year 2027.

Minerals 260 Managing Director Luke McFadyen said regarding the project:

Fifteen months after acquiring the Bullabulling Gold Project, we are presenting outcomes of our PFS and a Maiden Ore Reserve. We always believed Bullabulling could become a significant gold operation, and today’s outcomes confirm the potential for this high-margin, large-scale, long-life Project. Our target of delivering Bullabulling into production by the end of 2028 will establish Minerals 260 as the next mid-tier gold producer on the ASX. With an NPV of $2.3 billion, an IRR of 43% and $510M of average annual EBITDA, Bullabulling is set to deliver significant growth and value for our shareholders.

Shares in this ASX gold company looking cheap

Morgans said, importantly, that the PFS was completed using the previous 4.5 million-ounce gold resource, with an upgraded 6.2 million-ounce resource providing scope for further resource growth.

They added:

The market has reacted negatively to the PFS, which we believe is largely a product of the crystallisation of a sizeable upfront capital requirement rather than any deterioration in project quality. While pre-production capital of ~A$855m is significant, we view it as appropriate for an asset of Bullabulling’s scale, longevity and economic returns, with the project’s strong cash-generative profile expected to support favourable financing outcomes.

Morgans is anticipating first production in mid FY29 with an average output of about 150,000 ounces per year initially.

They added:

We assume a Stage 2 expansion, funded from operating cash flow, is commissioned in 2H FY31, increasing production towards ~200kozpa. Beyond lifting the production profile, the larger-scale operation has the potential to benefit from economies of scale and lower unit operating costs, although we do not currently incorporate these benefits into our base case.

Morgans has a price target of $1.38 on Minerals 260 shares.

The post This oversold ASX gold developer could more than double: Broker appeared first on The Motley Fool Australia.

More reading

• Which ASX 200 sectors paid the highest dividend yields in FY26?
• BHP shares may not double in 12 months but this ASX mining share could
• 5 things to watch on the ASX 200 on Thursday
• 13 ASX 200 shares that doubled in value in FY26
• 5 best ASX 200 mining shares of FY26

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are 0.5% higher on Friday at 8,801.8 points.

Brokers have indicated continuing confidence in several ASX 200 shares this week.

Let’s take a look.

Telstra Group Ltd (ASX: TLS)

The Telstra share price is $4.99, up 0.1% today and up 2.2% over 12 months.

Morgan Stanley reiterated its buy rating on Telstra shares on Wednesday.

The broker lowered its 12-month share price target from $5.40 to $5.30.

This implies potential capital gains of 6% in FY27.

Liontown Ltd (ASX: LTR)

The Liontown share price is $1.47, down 0.5% today and up 83% over 12 months.

The lithium producer was one of the 5 top ASX 200 mining shares for capital growth in FY26.

Macquarie renewed its buy rating on Liontown shares with a $2.30 target this week.

This suggests a potential 57% upside ahead.

Life360 Inc (ASX: 360)

The Life360 share price is $25.82, down 0.4% today and down 21% over 12 months.

Citi reiterated its buy rating on Life360 shares on Tuesday.

The broker raised its target from $28.25 to $31.95.

This implies potential capital gains of 24% ahead.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is $199.48, down 5.1% today and down 37% over 12 months.

However, that 12-month performance belies this ASX 200 healthcare share’s incredible comeback in CY26.

Pro Medicus shares hit a 52-week low of $107.75 on 24 February. Since then, they’ve ripped 85% higher.

And since the broader healthcare sector pivoted on 3 June, Pro Medicus shares have outperformed with a 25% gain.

That compares to a 21% increase in the S&P/ASX 200 Health Care Index (ASX: XHJ) since 3 June.

Citi sees more room for growth, and reiterated its buy rating with a $240 target this week.

This suggests another 20% upside ahead.

South32 Ltd (ASX: S32)

The South32 share price is $4.02, up 5.2% today and up 32% over 12 months.

Morgan Stanley maintained its buy rating on the ASX 200 mining share this week.

The broker shaved its 12-month target down from $4.85 to $4.75.

This implies a potential 18% upside ahead.

BHP Group Ltd (ASX: BHP)

The BHP share price is $58.28, up 2.5% today and up 52% over 12 months.

Morgan Stanley renewed its buy rating on BHP shares with a $67.50 target this week.

This suggests a potential 15% upside in the new financial year.

WiseTech Global Ltd (ASX: WTC)

The WiseTech share price is $34.24, down 1.1% today and down 70% over 12 months.

This tech share was the fastest faller of the ASX 200 in FY26.

Citi anticipates a strong recovery for WiseTech shares and renewed its buy rating this week.

However, the broker cut its 12-month target significantly from $65.65 to $52.

This still implies potential capital gains of 52% in FY27.

Paladin Energy Ltd (ASX: PDN)

The Paladin Energy share price is $10.15, up 5.1% today and up 46% over 12 months.

Morgan Stanley kept its buy call on the ASX 200 energy share but lowered its target from $13.65 to $11.95 this week.

This suggests a potential 17% upside ahead.

Coles Group Ltd (ASX: COL)

The Coles share price is $23.58, down 0.4% today and up 15% over 12 months.

UBS renewed its buy rating on the ASX 200 consumer staples share with a $25.50 target on Monday.

This suggests a potential 8% upside ahead.

The post 9 ASX 200 shares with reiterated buy calls this week appeared first on The Motley Fool Australia.

More reading

• Here’s what brokers tip for BHP shares over the next 12 months
• Which is the best buy, Coles shares or Wesfarmers shares?
• Two ASX tech shares hinge on rebuilding trust and growth. Here’s how they can turn around
• The bull and bear case for CBA and BHP shares
• How much do I need in my superannuation to get $52,000 per year in passive income?

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has positions in BHP Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360, Macquarie Group, and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Life360, Telstra Group, and WiseTech Global. The Motley Fool Australia has recommended BHP Group, Macquarie Group, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.